FLX475 in Combination With Ipilimumab in Advanced Melanoma

NCT04894994 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Change in clinical landscape

Conditions

Advanced Melanoma

Interventions

DRUG: FLX475
DRUG: Ipilimumab

Sponsor

RAPT Therapeutics, Inc.